Arranon, Atriance(nelarabine)
Arranon, Atriance, Nelarabine (nelarabine) is a small molecule pharmaceutical. Nelarabine was first approved as Arranon on 2005-10-28. It is used to treat t-cell leukemia in the USA. It has been approved in Europe to treat precursor t-cell lymphoblastic leukemia-lymphoma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Arranon, Nelarabine
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arranon | New Drug Application | 2024-09-30 |
| nelarabine | ANDA | 2025-01-03 |
| nelearbine | ANDA | 2023-06-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| t-cell leukemia | — | D015458 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9261 | Injection, nelarabine, 50 mg |
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 5 | 11 | 6 | — | 4 | 24 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 4 | 13 | 6 | — | 4 | 24 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | 10 | 6 | — | 2 | 18 |
| Lymphoma | D008223 | — | C85.9 | 3 | 10 | 4 | — | 1 | 17 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 2 | 8 | 1 | — | — | 9 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 5 | 3 | — | — | 8 |
| Mucositis | D052016 | EFO_1001898 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 1 | 5 | — | — | 1 | 6 |
| T-cell lymphoma | D016399 | — | — | — | 4 | — | — | — | 4 |
| T-cell leukemia | D015458 | — | — | — | 3 | — | — | — | 3 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 3 | — | — | — | 3 |
| Acute disease | D000208 | — | — | — | 1 | — | — | 1 | 2 |
| Mycoses | D009181 | — | B35-B49 | — | 2 | — | — | — | 2 |
| Sezary syndrome | D012751 | — | C84.1 | — | 2 | — | — | — | 2 |
| Mycosis fungoides | D009182 | — | C84.0 | — | 2 | — | — | — | 2 |
| T-cell lymphoma cutaneous | D016410 | — | — | — | 2 | — | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 2 | — | — | — | 2 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 1 | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Plasmacytoma | D010954 | — | C90.3 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | — | — | — | — | 1 | 1 |
| Myeloid leukemia | D007951 | — | C92 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nelarabine |
| INN | nelarabine |
| Description | Nelarabine is a purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G). It has a role as an antineoplastic agent, a DNA synthesis inhibitor and a prodrug. It is a purine nucleoside, a beta-D-arabinoside and a monosaccharide derivative. It is functionally related to a guanine and a 9-beta-D-arabinofuranosylguanine. |
| Classification | Small molecule |
| Drug class | antineoplastics (arabinofuranosyl derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 121032-29-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201112 |
| ChEBI ID | 63612 |
| PubChem CID | 3011155 |
| DrugBank | DB01280 |
| UNII ID | 60158CV180 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,134 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arranon, Nelarabine, Nelearbine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,041 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use